[A fundamental study on accumulation of [125I]IBZM in the rat striatum and on effect of non-labeled ligand].
Iodo-125-labeled iodobenzamide ([125I]IBZM) is used as a specific binding radioligand to dopamine D2 receptors with high affinity and selectivity. The radioligand was homogenously distributed in the whole brain initially after administration, and rapidly washed out from the dopamine receptor-poor area followed by persistent retention in the striatum. Regression curve generated from striatum/cortex PSL ratio indicated the constant washout rate from striatum and cortex respectively. In the pretreated rat by cold benzamide (2 mg/kg), the accumulation of the radioligand was significantly suppressed in the striatum (48.8%). Iodine-125-labeled iodo-benzamide has the promise for investigation of dopamine D2 receptors in the living brain.
Ishikawa
N
N
Institute of Clinical Medicine, Tsukuba University.
Nakamura
T
T
Motoji
N
N
Satou
M
M
Takeda
T
T
Wu
J
J
Shigematsu
A
A
D000818:Animals; D001345:Autoradiography; D001549:Benzamides / Q000493:pharmacokinetics*; D001812:Blood-Brain Barrier; D003342:Corpus Striatum / Q000378:metabolism*; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D011759:Pyrrolidines / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012044:Regression Analysis
D001549:Benzamides; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide